FindTrial
Sign In

Phase I/II study of HP-3060 in patients with allergic rhinitis.

A multiple dose study of HP-3060 in patients with allergic rhinitis.

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080222141
Enrollment
Unknown
Registered
2013-07-10
Start date
2013-07-10
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic rhinitis

Interventions

investigational material(s) Generic name etc : HP-3060 INN of investigational material : Therapeutic category code : 269 Other agents for epidermis Dosage and Administration for Investigational mater

Sponsors

Hisamitsu Pharmaceutical Co., Inc.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Subjects with a disease duration of 2 years or more and a positive result for serum specific IgE antibody on quantitative assessment.

Exclusion criteria

Exclusion criteria: - Allergic rhinitis complicated by other types of rhinitis, such as infectious rhinitis, vasomotor rhinitis, or eosinophilic rhinitis - Allergic rhinitis complicated by chronic sinusitis - Hyposensitization therapy or nonspecific immunotherapy

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026